145 related articles for article (PubMed ID: 38739215)
41. Isolated peripheral enthesitis and/or dactylitis: a subset of psoriatic arthritis.
Salvarani C; Cantini F; Olivieri I; Macchioni P; Niccoli L; Padula A; Ferri S; Portioli I
J Rheumatol; 1997 Jun; 24(6):1106-10. PubMed ID: 9195517
[TBL] [Abstract][Full Text] [Related]
42. Treatment of Dactylitis and Enthesitis in Psoriatic Arthritis with Biologic Agents: A Systematic Review and Metaanalysis.
Mourad A; Gniadecki R
J Rheumatol; 2020 Jan; 47(1):59-65. PubMed ID: 30824641
[TBL] [Abstract][Full Text] [Related]
43. Effects of secukinumab on synovitis and enthesitis in patients with psoriatic arthritis: 52-week clinical and ultrasound results from the randomised, double-blind ULTIMATE trial with open label extension.
D'Agostino MA; Carron P; Gaillez C; Conaghan PG; Naredo E; López-Rdz A; Šenolt L; Burgos-Vargas R; Hanova P; Padovano I; Cazenave T; Stoenoiu MS; Backhaus M; Mouterde G; Bao W; Goyanka P; Boers M; Schett G
Semin Arthritis Rheum; 2023 Dec; 63():152259. PubMed ID: 37660536
[TBL] [Abstract][Full Text] [Related]
44. [Benefit of ultrasound in the phenotype recognition of psoriatic arthritis].
Song ZB; Geng Y; Deng XR; Zhang XH; Zhang ZL
Beijing Da Xue Xue Bao Yi Xue Ban; 2021 Dec; 53(6):1061-1066. PubMed ID: 34916682
[TBL] [Abstract][Full Text] [Related]
45. Methotrexate achieves major cDAPSA response, and improvement in dactylitis and functional status in psoriatic arthritis.
Appani SK; Devarasetti PK; Irlapati RVP; Rajasekhar L
Rheumatology (Oxford); 2019 May; 58(5):869-873. PubMed ID: 30590763
[TBL] [Abstract][Full Text] [Related]
46. Effect of tofacitinib on dactylitis and patient-reported outcomes in patients with active psoriatic arthritis: post-hoc analysis of phase III studies.
Orbai AM; Mease PJ; Helliwell PS; FitzGerald O; Fleishaker DL; Mundayat R; Young P
BMC Rheumatol; 2022 Sep; 6(1):68. PubMed ID: 36045453
[TBL] [Abstract][Full Text] [Related]
47. Apremilast monotherapy for long-term treatment of active psoriatic arthritis in DMARD-naïve patients.
Wells AF; Edwards CJ; Kivitz AJ; Bird P; Guerette B; Delev N; Paris M; Teng L; Aelion JA
Rheumatology (Oxford); 2022 Mar; 61(3):1035-1043. PubMed ID: 34100922
[TBL] [Abstract][Full Text] [Related]
48. Therapeutic Effects of Apremilast on Enthesitis and Dactylitis in Real Clinical Setting: An Italian Multicenter Study.
Lo Gullo A; Becciolini A; Parisi S; Del Medico P; Farina A; Visalli E; Dal Bosco Y; Molica Colella AB; Lumetti F; Caccavale R; Scolieri P; Andracco R; Girelli F; Bravi E; Colina M; Volpe A; Ianniello A; Ditto MC; Nucera V; Franchina V; Platé I; Di Donato E; Amato G; Salvarani C; Bernardi S; Lucchini G; De Lucia F; Molica Colella F; Santilli D; Mansueto N; Ferrero G; Marchetta A; Arrigoni E; Foti R; Sandri G; Bruzzese V; Paroli M; Fusaro E; Ariani A
J Clin Med; 2023 Jun; 12(12):. PubMed ID: 37373587
[TBL] [Abstract][Full Text] [Related]
49. Patient-reported outcomes and the association with clinical response in patients with active psoriatic arthritis treated with golimumab: findings through 2 years of a phase III, multicenter, randomized, double-blind, placebo-controlled trial.
Kavanaugh A; McInnes IB; Krueger GG; Gladman D; Beutler A; Gathany T; Mack M; Tandon N; Han C; Mease P
Arthritis Care Res (Hoboken); 2013 Oct; 65(10):1666-73. PubMed ID: 23666608
[TBL] [Abstract][Full Text] [Related]
50. Efficacy and safety of tofacitinib for chronic plaque psoriasis and psoriatic arthritis: a systematic review and meta-analysis of randomized controlled trials.
Dai Q; Zhang Y; Liu Q; Zhang C
Clin Rheumatol; 2024 May; 43(5):1605-1613. PubMed ID: 38517652
[TBL] [Abstract][Full Text] [Related]
51. Long-Term Efficacy and Safety of Risankizumab in Patients with Active Psoriatic Arthritis: Results from a 76-Week Phase 2 Randomized Trial.
Mease PJ; Kellner H; Morita A; Kivitz AJ; Aslanyan S; Padula SJ; Topp AS; Eldred A; Behrens F; Papp KA
Rheumatol Ther; 2022 Oct; 9(5):1361-1375. PubMed ID: 35931879
[TBL] [Abstract][Full Text] [Related]
52. Biological DMARD efficacy in psoriatic arthritis: a systematic literature review and meta-analysis on articular, enthesitis, dactylitis, skin and functional outcomes.
Simons N; Degboé Y; Barnetche T; Cantagrel A; Ruyssen-Witrand A; Constantin A
Clin Exp Rheumatol; 2020; 38(3):508-515. PubMed ID: 31969228
[TBL] [Abstract][Full Text] [Related]
53. Enthesitis in patients with psoriatic arthritis treated with secukinumab or adalimumab: a post hoc analysis of the EXCEED study.
Kaeley GS; Schett G; Conaghan PG; McGonagle D; Behrens F; Goupille P; Gaillez C; Parikh B; Bakewell C
Rheumatology (Oxford); 2024 Jan; 63(1):41-49. PubMed ID: 37097894
[TBL] [Abstract][Full Text] [Related]
54. Measuring treatment effect on psoriatic arthritis-related domains: insights from the SPIRIT-H2H study at weeks 24 and 52.
Behrens F; Leage SL; Sapin C; Baou CE; De La Torre I; Meszaros G; Schett G; Combe B; van den Bosch F; Gossec L
Clin Rheumatol; 2021 Dec; 40(12):4943-4954. PubMed ID: 34515902
[TBL] [Abstract][Full Text] [Related]
55. Efficacy and safety of risankizumab in moderate-to-severe plaque psoriasis (UltIMMa-1 and UltIMMa-2): results from two double-blind, randomised, placebo-controlled and ustekinumab-controlled phase 3 trials.
Gordon KB; Strober B; Lebwohl M; Augustin M; Blauvelt A; Poulin Y; Papp KA; Sofen H; Puig L; Foley P; Ohtsuki M; Flack M; Geng Z; Gu Y; Valdes JM; Thompson EHZ; Bachelez H
Lancet; 2018 Aug; 392(10148):650-661. PubMed ID: 30097359
[TBL] [Abstract][Full Text] [Related]
56. Effectiveness of Tofacitinib in Patients Initiating Therapy for Psoriatic Arthritis: Results from the CorEvitas Psoriatic Arthritis/Spondyloarthritis Registry.
Mease PJ; Young P; Fallon L; Mundayat R; Dina O; Blachley T; Middaugh N; Ogdie A
Rheumatol Ther; 2024 Apr; 11(2):313-329. PubMed ID: 38252211
[TBL] [Abstract][Full Text] [Related]
57. Impact of Enthesitis on Psoriatic Arthritis Patient-Reported Outcomes and Physician Satisfaction with Treatment: Data from a Multinational Patient and Physician Survey.
Orbai AM; Birt JA; Holdsworth EA; Booth N; Malatestinic WN; Sprabery AT; Reginato AM
Rheumatol Ther; 2020 Dec; 7(4):937-948. PubMed ID: 33052584
[TBL] [Abstract][Full Text] [Related]
58. Targeted systemic therapies for psoriatic arthritis: a systematic review and comparative synthesis of short-term articular, dermatological, enthesitis and dactylitis outcomes.
McInnes IB; Sawyer LM; Markus K; LeReun C; Sabry-Grant C; Helliwell PS
RMD Open; 2022 Mar; 8(1):. PubMed ID: 35321874
[TBL] [Abstract][Full Text] [Related]
59. Efficacy of ustekinumab in biologic-naïve patients with psoriatic arthritis by prior treatment exposure and disease duration: data from PSUMMIT 1 and PSUMMIT 2.
McInnes IB; Chakravarty SD; Apaolaza I; Kafka S; Hsia EC; You Y; Kavanaugh A
RMD Open; 2019; 5(2):e000990. PubMed ID: 31565242
[TBL] [Abstract][Full Text] [Related]
60. Apremilast for biologic-naïve, peripheral psoriatic arthritis, including patients with early disease: results from the APROACH observational prospective study.
Sfikakis PP; Vassilopoulos D; Katsifis G; Vosvotekas G; Dimitroulas T; Sidiropoulos P; Vounotrypidis P; Bogdanos DP; Georgountzos AΙ; Bounas AG; Georgiou P; Gazi S; Kataxaki E; Liossis SN; Theodorou E; Papagoras C; Theotikos E; Vlachoyiannopoulos P; Voulgari PV; Kekki A; Antonakopoulos N; Boumpas DT
Rheumatol Int; 2023 May; 43(5):889-902. PubMed ID: 36856816
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
